Abstract:Osteosarcoma is the most common primary malignant tumor of bone. Except for the improvement in five-year survival achieved by the adoption of neoadjuvant chemotherapy strategy, there are nearly no improvement for the treatment of osteosarcoma in the past 30years, especially for the patients with metastatic disease. Immunotherapy has been successfully applied in some tumors. The survival of osteosarcoma patients enrolled in several clinical immunotherapy trials did be improved in the past. Immunotherapy might further improve the therapy result of osteosarcoma patients besides neoadjuvant chemotherapy. But there still are many problems needed to be solved before clinically successful application. Immune escape is one of the main obstacles hindering the immunotherapy for osteosarcoma. No effective tumor antigens, or in other words, attenuated immunogenicity is one of the main mechanisms of immune escape. So the key point of immunotherapy for osteosarcoma is to find out an effective target through which the immune system can recognize this tumor and attack it. Genetic modification of immune system may circumvent this problem by enhancing the capacity of immune system. Chimeric antigen receptor (CAR), an artificial receptor generated by genetic manipulation, is a promising technique. The CAR technique can circumvent the restriction of major histocompatibility in antigen recognition for T cells, and is more effective than the corresponding antibody to get rid of tumor cells. But short persistence of the CAR expressing T cells in vivo is the main problem of CAR technique in current research. This problem is believed to have some relation to the immunogenicity of the artificial receptor because the antigen recognizing portion of receptor is derived from monoclonal antibody. So we believe that the elimination of the immunogenicity of CAR might prolong the persistence of CAR expressing T cells in vivo and put forward a hypothesis that the antigen binding portion of CAR could be derived from the antibody against osteosarcoma antigen from the same patient with osteosarcoma by methods such as antibody phage display, BRASIL technique. We believe that CAR expressing T cells constructed by this strategy would persist longer and are more effective to eradicate osteosarcoma cells. In addition, this treatment strategy is an individualized treatment because an effective target specific to the CAR could be found. Therefore the immune escape of osteosarcoma would be surmounted and the survival of patients would be improved.

A Caspase-6 and Anti-Her2 Antibody Chimeric Tumor-Targeted Proapoptotic Molecule Decreased Metastasis of Human Osteosarcoma.

A novel recombinant immunocasp-6 fusion gene specifically and efficiently suppresses HER2-overexpressing osteosarcoma

Targeted Pro-Apoptotic Effect of Human Recombinant Caspase-6 Fusion Protein on Osteosarcoma SOSP-9607 Cells

A Caspase-6 and Anti-Human Epidermal Growth Factor Receptor-2 (HER2) Antibody Chimeric Molecule Suppresses the Growth of HER2-Overexpressing Tumors1

Anti-CD166/4-1BB Chimeric Antigen Receptor T Cell Therapy for the Treatment of Osteosarcoma

Scfv-Mediated Delivery of Truncated BID Suppresses HER2-positive Osteosarcoma Growth and Metastasis

Combining Photothermal Ablation-Based Vaccine with Immune Checkpoint Blockade for Synergistic Osteosarcoma Immunotherapy

A Novel Recombinant Immuno-Tbid With A Furin Site Effectively Suppresses The Growth Of Her2-Positive Osteosarcoma Cells In Vitro

The Pro-Apoptotic Effect of HER2 Targeted Recombinant Truncated Bid Fusion Protein on Osteosarcoma Cells

Specific Tumoricidal Activity Of A Secreted Proapoptotic Protein Consisting Of Her2 Antibody And Constitutively Active Caspase-3

HER2-targeted recombinant protein immuno-caspase-6 effectively induces apoptosis in HER2-overexpressing GBM cells in vitro and in vivo

Checkpoint Blockade in Combination With Doxorubicin Augments Tumor Cell Apoptosis in Osteosarcoma.

Targeted delivery of PD‐L1‐derived phosphorylation‐mimicking peptides by engineered biomimetic nanovesicles to enhance osteosarcoma treatment

Potent Inhibition of Human Gastric Cancer by HER2-directed Induction of Apoptosis with Anti-Her2 Antibody and Caspase-3 Fusion Protein.

Pro-apoptotic Effect of Recombinant Anti-Her2 Fusion Protein ScFv/tBid Gene on Osteosarcoma E10 Cells

Biomimetic Targeted Co‐Delivery System Engineered from Genomic Insights for Precision Treatment of Osteosarcoma

Synergistic treatment of osteosarcoma with biomimetic nanoparticles transporting doxorubicin and siRNA

Enhanced pyroptosis induction with pore-forming gene delivery for osteosarcoma microenvironment reshaping

Auto T Cells Expressing Chimeric Antigen Receptor Derived from Auto Antibody Might Be a New Treatment for Osteosarcoma.

The Effect of Direct Translocation Across Endosomes on the Cytotoxicity of the Recombinant Protein E23sfv-Fdt-casp6 to HER2 Positive Gastric Cancer Cells

CPPs-modified chitosan as permeability-enhancing chemotherapeutic combined with gene therapy nanosystem by thermosensitive hydrogel for the treatment of osteosarcoma